Table 3.
Risk of cancer between ranitidine users and famotidine users.
| Cancer | Ranitidine (n, %) | Famotidine (n, %) | p-Value | Hazard Ratio (95% CI) | p-Value |
|---|---|---|---|---|---|
| Overall | 3018 (7.45) | 765 (7.56) | 0.739 | 0.99 (0.91–1.07) | 0.716 |
| Liver | 400 (0.99) | 117 (1.16) | 0.148 | 0.85 (0.69–1.05) | 0.133 |
| Colorectal | 359 (0.89) | 92 (0.91) | 0.878 | 0.98 (0.78–1.23) | 0.832 |
| Biliary | 93 (0.23) | 19 (0.19) | 0.493 | 1.22 (0.75–2.00) | 0.422 |
| Stomach | 450 (1.11) | 106 (1.05) | 0.616 | 1.06 (0.86–1.31) | 0.580 |
| Lung | 473 (1.17) | 119 (1.18) | 0.992 | 0.99 (0.81–1.21) | 0.951 |
| Prostate | 173 (0.43) | 43 (0.42) | >0.999 | 1.01 (0.72–1.40) | 0.974 |
| Kidney | 72 (0.18) | 23 (0.23) | 0.369 | 0.78 (0.49–1.25) | 0.306 |
| Bladder | 118 (0.29) | 21 (0.21) | 0.181 | 1.41 (0.88–2.24) | 0.151 |
| Uterine | 46 (0.11) | 10 (0.10) | 0.815 | 1.15 (0.58–2.28) | 0.689 |
| Breast | 108 (0.27) | 33 (0.33) | 0.365 | 0.82 (0.55–1.21) | 0.313 |
| Thyroid | 159 (0.39) | 37 (0.37) | 0.761 | 1.07 (0.75–1.54) | 0.694 |